Evidence map›Paper›PMID 40772530›Full record

ArticleHeadache

Calcitonin gene-related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme-linked immunosorbent assays.

Michael L Garelja, Tayla A Rees, Debbie L Hay

Abstract readComparative Study
In one paragraph

Article in Headache. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael L GareljaDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0001-5332-1236
Tayla A ReesHeadache Group, Wolfson Sensory, Pain, and Regeneration Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
Debbie L HayDepartment of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-9558-5122

Funding

International Headache SocietyMarsden Fund
6 · The paper itself

Abstract

OBJECTIVES/

backgroundThis study was undertaken to test the ability of a widely used enzyme-linked immunosorbent assay (ELISA) kit to detect calcitonin gene-related peptide (CGRP) isoforms to better understand currently published clinical data. There is significant interest in measuring CGRP as a biomarker in headache and migraine research, with ELISAs being the preferred detection method. ELISAs use antibodies that have been raised against an antigen to allow selective quantification of an analyte in a sample. Understanding the specificity of these antibodies is crucial to interpreting results. One commercially available kit (Cusabio CSB-E08210h, Kit A) is purported to specifically detect β-CGRP (one of the two CGRP isoforms) over α-CGRP and has been used to investigate the potential for CGRP to be used as a biomarker for migraine. We investigated the ability of this kit to detect multiple isoforms of CGRP to better interpret published clinical results. We used a second ELISA kit (Bertin Bioreagent, A05481, Kit B) that is nonselective for the different CGRP isoforms as a control to ensure the CGRP we used could be detected in ELISAs.

methodsWe performed ELISAs according to the manufacturer's instructions, testing concentrations within the advertised range of each kit. At least three independent experiments were conducted for each kit.

resultsKit B was able to detect both human and mouse α-CGRP and β-CGRP with a high degree of reproducibility. In contrast, Kit A did not detect bioactive forms of human α-CGRP or β-CGRP, nor mouse α-CGRP or β-CGRP.

conclusionKit A may not be reliable for future studies, as it does not appear to detect mature bioactive CGRP. Importantly, conclusions from previous studies that used this kit may need to be reevaluated, as it is not clear what analyte the kit has detected. Our findings also highlight the importance of understanding research tools to ensure accurate interpretation of results.

Indexed as

Calcitonin Gene-Related PeptideHeadacheReagent Kits, DiagnosticAnimalsBiomarkersEnzyme-Linked Immunosorbent AssayHumansMiceMigraine DisordersProtein IsoformsReproducibility of ResultsBiomarkersCalcitonin Gene-Related PeptideProtein IsoformsReagent Kits, Diagnosticbiomarkercalcitonin gene‐related peptideenzyme‐linked immunosorbent assayimmunoassaymigraine

Identifiers

PMID40772530
PMCPMC12638522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.